Related Experiment Video
Updated: Aug 15, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Lung cancer chemotherapy, new treatment and related patents
Attapon Cheepsattayakorn, Ruangrong Cheepsattayakorn1
110th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road, Changklan Muang, Chiang Mai 50100, Thailand and 10th Office of Disease Prevention and Control, 447 Lumphun Road, Watgate Muang, Chiang Mai 50,000, Thailand. attaponche@yahoo.com.
Abstract:
The majority of patients with lung cancer present with advanced stage which contributes to death of more people than any other malignancy in the world. The discovery of a number of lung cancer-molecular alterations contributes to uniquely targeted therapies with specific inhibitors for non-small cell lung cancer such as erlotinib, gefitinib and crizotinib. Pemetrexed has statistically shown significantly reduced adverse side effects of drug compared with docetaxel. V1801, an analog of gefitinib may overcome gefitinib resistance in patients with non-small cell lung cancer. Thymosin α1, an immunomodulator significantly improves patient's quality of life by enhancing T-cell function, stimulation of Tcell maturation and differentiation. Various novel compounds and chemotherapeutics were introduced in 2013 patents such as taxane, quinazoline, arylamino purine, benzodiazepine, pyrrolopyrimidine, nitrobenzamide, cyclopropane amide, 4-iodo-3-nitrobenzamide, heteroaryl (alkyl) dithiocarbamate, and histone deacetylase in treating non-small-cell lung cancer and piperidine, piperazine, picoplatin, and arsenic trioxide in treating small-cell lung cancer.
Insights
Targeted therapies and novel compounds show promise for advanced lung cancer. Research highlights improved quality of life and potential to overcome drug resistance in non-small cell lung cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Lung cancer is a leading cause of cancer-related death worldwide, often diagnosed at advanced stages.
- Molecular alterations in lung cancer have led to the development of targeted therapies.
- Existing treatments face challenges such as drug resistance and adverse side effects.
Purpose of the Study:
- To review recent advancements in lung cancer therapeutics, focusing on targeted therapies and novel compounds.
- To explore strategies for overcoming drug resistance in non-small cell lung cancer (NSCLC).
- To highlight agents that improve patient quality of life and reduce treatment-related side effects.
Main Methods:
- Review of scientific literature and patent filings (2013) related to lung cancer treatments.
- Analysis of targeted inhibitors, immunomodulators, and novel chemotherapeutic agents.
- Comparison of efficacy and side effect profiles of different treatment options.
Main Results:
- Targeted inhibitors like erlotinib, gefitinib, and crizotinib are effective for NSCLC with specific molecular alterations.
- Pemetrexed demonstrates a better side effect profile compared to docetaxel.
- V1801, a gefitinib analog, may address gefitinib resistance; Thymosin α1 improves quality of life by enhancing T-cell function.
Conclusions:
- Novel compounds and targeted therapies offer new avenues for treating both non-small cell and small cell lung cancer.
- Strategies to overcome drug resistance and improve patient quality of life are crucial in advanced lung cancer management.
- Continued research into molecular alterations and therapeutic agents is essential for improving patient outcomes.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers